AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The AML96 study examines the feasibility of a risk-adapted postremission treatment strategy
including related and unrelated allogeneic stem cell transplantation for high risk AML
patients and related allogeneic and autologous stem cell transplantation for standard risk
AML patients in a multi-center setting. Furthermore it randomizes patients between
intermediate-dose Cytarabine vs high-dose Cytarabine within the first postremission-course.